CSIMarket Company Name, Ticker, Competitors, else..
 
Guardion Health Sciences Inc   (NASDAQ: GHSI)
Other Ticker:  
 
 
Price: $3.2200 $-0.07 -2.128%
Day's High: $3.29 Week Perf: -2.42 %
Day's Low: $ 3.22 30 Day Perf: -41.88 %
Volume (M): 5 52 Wk High: $ 18.00
Volume (M$): $ 15 52 Wk Avg: $8.62
Open: $3.22 52 Wk Low: $3.04



 Market Capitalization (Millions $) 4
 Shares Outstanding (Millions) 1
 Employees -
 Revenues (TTM) (Millions $) 9
 Net Income (TTM) (Millions $) 6
 Cash Flow (TTM) (Millions $) 6
 Capital Exp. (TTM) (Millions $) 0

Guardion Health Sciences Inc
Guardion Health Sciences Inc is a healthcare company that specializes in developing and commercializing medical nutrition and diagnostics solutions. The company focuses on improving overall health and wellness, with a particular emphasis on eye health. Guardion Health Sciences offers various products and services, including nutraceuticals and medical foods to support healthy vision, as well as genetic testing and diagnostic services to identify and manage various health conditions. The company aims to provide personalized healthcare solutions to individuals and healthcare professionals globally.


   Company Address: 2925 Richmond Avenue Houston 77098 TX
   Company Phone Number: 873-5141   Stock Exchange / Ticker: NASDAQ GHSI


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
LFVN        8.26% 
NATR   -11.74%    
HLF   -9.65%    
NUS        1.12% 
NYMT        0.15% 
USNA   -11.91%    
• View Complete Report
   



Guardion Health Sciences Inc

Analysis of Guardion Health Sciences Inc's Financial Performance and Reasons for Slipping into Red at GHSI



Guardion Health Sciences Inc, a prominent player in the health sciences industry, recently reported its financial results for the time-frame closing March 31, 2024. The company experienced a significant decrease in earnings per share (EPS) and revenue compared to the previous reporting season. This article will delve into the key findings from Guardion's financial statements and shed light on the reasons behind its negative performance.
EPS and Net Deficit:
Guardion Health Sciences Inc's earnings per share plummeted to $-3.71, in contrast to $0.42 per share a year ago. This decline suggests a substantial decrease in profitability over the past year. Further, the company's net deficit for the same financial period amounted to $-4.747 million, showcasing a drastic shift from a balanced book in the previous reporting season.
Guardion Health Sciences Inc

Guardion Health Sciences Inc. Shines with Strong Financial Performance in Recent Fiscal Period

The stock market has been buzzing with excitement as Guardion Health Sciences Inc (GHSI) has reported some impressive numbers for the October to December 31, 2023 fiscal span. Investors were pleased to see that GHSI turned a profit of $0.33 per share, a significant improvement from the loss of $0.16 per share in the same period a year earlier. This represents a 14.85% growth in earnings per share from the previous reporting season.
Furthermore, GHSI saw a 10.505% increase in revenue, reaching $4.35 million compared to $3.94 million in the corresponding reporting season a year prior. Sequentially, revenue surged by an impressive 76.799% from $2.46 million. This growth in revenue and profitability is a positive sign for the company as it continues to expand and enhance its market position.
Guardion Health Sciences Inc

Guardion Health Sciences Inc witnesses impressive double-digit growth during July-September 2023 period

uardion Health Sciences Inc. (GHSI) recently reported positive third-quarter earnings for the interval July to September 2023. Despite this encouraging news, there are several reasons to remain bearish on the stock. This article will delve into the potential challenges facing GHSI in the major pharmaceutical preparations sector and analyze its financial performance and market trends.
Revenue Growth and Earnings Improvement:
While GHSI showcased an admirable revenue growth of 17.818% to $2.46 million in the corresponding reporting season a year ago, it is essential to assess this growth in the context of the industry's overall performance. The observed revenue growth may not be sustainable, as many entities within the sector are experiencing declining top-line figures and dwindling transactions.
Guardion Health Sciences Inc

Guardion Health Sciences Inc Reports Slight Revenue Downturn during Q2 2023 Earnings Season

Guardion Health Sciences Inc Reports Decreased Revenue and Increased Shortfall
Guardion Health Sciences Inc, a major player in the pharmaceutical preparations industry, has recently released its latest financial reports for the most recent fiscal period. The company's performance has witnessed a downward spiral during this period, as it reported substantial declines in revenue and a significant increase in the shortfall per share compared to the previous year.
In terms of earnings per share (EPS), Guardion Health Sciences Inc's shortfall per share for the most recent fiscal period stood at $-0.93, a notable increase compared to $-0.03 reported a year ago. Moreover, the company experienced a decline in EPS from $0.42 per share in the preceding quarter. These figures indicate a concerning trend for the company's profitability.






Guardion Health Sciences Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com